1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNeuroImpact Fund is sponsored by Epilepsy Foundation (in partnership with Iaso Ventures). The NeuroImpact Fund is a mission-driven initiative dedicated to advancing innovative therapies, treatments, and technologies that transform epilepsy care.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Epilepsy Foundation Partners with Iaso Ventures to Launch the NeuroImpact Fund Venture Philanthropy Fund to Support Development of New Therapeutics, Diagnostics and Technologies BOWIE, Md. , March 20, 2024 /PRNewswire/ -- Today, the Epilepsy Foundation announced a transformative partnership with Iaso Ventures, a prominent venture capital firm, to establish the Iaso NeuroImpact Fund.
This innovative fund serves as a cornerstone for advancing the development of pioneering therapeutics, diagnostics, and technologies aimed at revolutionizing the landscape of care for epilepsy and seizure disorders.
Leveraging the professional investment acumen of Iaso Ventures and the profound research and clinical expertise of the Epilepsy Foundation, the NeuroImpact Fund is poised to catalyze breakthroughs in epilepsy treatment and support. The primary objective of the NeuroImpact Fund is to create a sustainable and enduring impact for people affected by epilepsy, as well as their families and caregivers.
Building upon a legacy of fostering innovation, the Epilepsy Foundation has been instrumental in advancing new products through initiatives such as the Shark Tank Competition, New Therapy Commercialization Grants, and the Epilepsy Innovation Institute.
Recognizing the critical need for bridging the gap between research and commercialization, the Foundation has identified the establishment of the NeuroImpact Fund as a primary source of funding to help accelerate therapies to stop seizures, find cures, and save lives.
"Throughout history, the Epilepsy Foundation has been at the forefront of supporting early-stage companies developing innovative solutions for epilepsy," said Bernice Martin Lee , chief executive officer, Epilepsy Foundation. "The NeuroImpact Fund represents a significant milestone in our journey, leveraging our collective expertise and resources to continue to drive innovation and improve the lives of people living with epilepsy."
Companies funded through the Iaso NeuroImpact Fund hold the promise to redefine epilepsy treatment paradigms with the most cutting-edge approaches. These innovative approaches encompass a diverse array of applications, including therapeutic development, seizure forecasting, rescue therapies, pediatric seizure prevention, and treatments for rare diseases.
Through strategic investments in these areas, the Epilepsy Foundation aims to enhance access to care and transform the lives of people across the epilepsy spectrum. "This collaboration represents an unprecedented opportunity to engage a wider spectrum of investors in driving tangible outcomes for people living with epilepsy," said Wasim Malik , managing partner, Iaso Ventures.
"The Iaso NeuroImpact Fund will not only benefit those affected by debilitating neurological disorders but also offer investors a unique opportunity to make a meaningful difference while reaping market-leading financial returns." For additional information about the NeuroImpact Fund and its initiatives, please visit epilepsy. com/NeuroImpact .
According to the World Health Organization , epilepsy is the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. The U.S. Centers for Disease Control & Prevention (CDC) estimates that 3. 4 million people in the United States are affected by epilepsy.
Epilepsy is the underlying tendency of the brain to produce seizures which are sudden abnormal bursts of electrical energy that disrupt brain functions. Iaso Ventures is a venture capital investment firm focused on the healthcare and life sciences sector. Headquartered in Boston , the firm invests in companies developing innovative technologies and solutions that have the potential to deliver transformative impact for patients.
The firm actively partners with leading research hospitals, disease foundations, pharma and medtech companies, and other key stakeholders to weave together a unique innovation ecosystem.
Empowered by this partner network, Iaso Ventures portfolio companies have pioneered ground-breaking applications in such diverse areas as AI-enabled drug discovery and clinical development, drug design and delivery platforms, first-in-class therapeutics, and digital technologies for full lifecycle support across the entire life sciences value chain.
SOURCE Epilepsy Foundation more press release views with Epilepsy Foundation of America Awards $250,000 at 14th Annual Shark Tank Competition The Epilepsy Foundation of America announced today that it has awarded $250,000 in funding at their 2026 Shark Tank Competition on Thursday, June 18, ... Joyce A.
Cramer to Receive Lifetime Accelerator Award for Transformative Contributions to Clinical Research and Epilepsy Innovation The Epilepsy Foundation of America is proud to announce that Joyce A. Cramer will be honored as this year's recipient of the Lifetime Accelerator... More Releases From This Source Banking & Financial Services News Releases in Similar Topics
According to the current listing, eligibility includes: Companies developing innovative solutions for epilepsy are eligible. The fund aims to support early-stage companies and those with the potential to redefine epilepsy treatment paradigms. Confirm the full requirements in the official notice before applying.
NeuroImpact Fund is funded by Epilepsy Foundation (in partnership with Iaso Ventures). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On June 1, DARPA and NSF announced AI Forge — a jointly governed forum that will fund university-led research on three thrusts: AI interpretability, AI control, and adversarial robustness. The RFI on sam.gov closes June 22, 2026, at 5:00 PM ET. Project Ventures awards run roughly $750K to $3M with one-year durations and multiple awards expected annually. Administration runs through a nonprofit, intellectual property will be shared via open-source licensing, and CAISI at NIST is the third partner. Here is what the 15 priority research challenges look like and how U.S. universities should respond.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleAt CGI on September 23, 2026, Global Impact Ventures committed $100 million over three years across economic opportunity, health, education, climate resilience and humanitarian needs. There is no application portal. The access route is the intermediary infrastructure — fiscal sponsorship, grantmaking administration, and a 250-organization network.
Read article